| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
|
Blackburn, Edith
|
|
2011
|
134 |
1 |
p. 53-59
|
artikel
|
| 2 |
An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease
|
Keyzer-Dekker, C. M. G.
|
|
2012
|
134 |
1 |
p. 253-258
|
artikel
|
| 3 |
Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer
|
Inao, Touko
|
|
2011
|
134 |
1 |
p. 89-100
|
artikel
|
| 4 |
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
|
Rugo, Hope S.
|
|
2011
|
134 |
1 |
p. 13-20
|
artikel
|
| 5 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
|
Li, Tianhong
|
|
2012
|
134 |
1 |
p. 345-352
|
artikel
|
| 6 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer
|
Yu, Ke-Da
|
|
2012
|
134 |
1 |
p. 307-313
|
artikel
|
| 7 |
Aromatase inhibitors and calcium absorption in early stage breast cancer
|
Tevaarwerk, Amye
|
|
2012
|
134 |
1 |
p. 245-251
|
artikel
|
| 8 |
Autologous microsurgical breast reconstruction and coronary artery bypass grafting: an anatomical study and clinical implications
|
Rozen, Warren M.
|
|
2012
|
134 |
1 |
p. 181-198
|
artikel
|
| 9 |
Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important?
|
Sanpaolo, Pietro
|
|
2011
|
134 |
1 |
p. 81-87
|
artikel
|
| 10 |
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
|
Powles, Trevor J.
|
|
2012
|
134 |
1 |
p. 299-306
|
artikel
|
| 11 |
Breast cancer incidence trends in European women aged 20–39 years at diagnosis
|
Merlo, D. F.
|
|
2012
|
134 |
1 |
p. 363-370
|
artikel
|
| 12 |
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy
|
Ottini, Laura
|
|
2012
|
134 |
1 |
p. 411-418
|
artikel
|
| 13 |
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat
|
Cortesi, Laura
|
|
2012
|
134 |
1 |
p. 435-441
|
artikel
|
| 14 |
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer
|
Spyratos, Frédérique
|
|
2012
|
134 |
1 |
p. 443-448
|
artikel
|
| 15 |
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
|
Hertz, Daniel L.
|
|
2012
|
134 |
1 |
p. 401-410
|
artikel
|
| 16 |
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity
|
Toulmonde, M.
|
|
2012
|
134 |
1 |
p. 325-332
|
artikel
|
| 17 |
Early diagnostic protein biomarkers for breast cancer: how far have we come?
|
Opstal-van Winden, Annemieke W. J.
|
|
2011
|
134 |
1 |
p. 1-12
|
artikel
|
| 18 |
Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
|
Kadra, Gais
|
|
2012
|
134 |
1 |
p. 449-451
|
artikel
|
| 19 |
14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers
|
Nakamura, Yukiko
|
|
2012
|
134 |
1 |
p. 229-236
|
artikel
|
| 20 |
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
|
Pestrin, Marta
|
|
2012
|
134 |
1 |
p. 283-289
|
artikel
|
| 21 |
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model
|
Mousseau, Yoanne
|
|
2011
|
134 |
1 |
p. 31-40
|
artikel
|
| 22 |
Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival
|
Shen, Jing
|
|
2012
|
134 |
1 |
p. 393-400
|
artikel
|
| 23 |
High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study
|
Onitilo, Adedayo A.
|
|
2012
|
134 |
1 |
p. 291-298
|
artikel
|
| 24 |
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
|
Girgert, Rainer
|
|
2012
|
134 |
1 |
p. 199-205
|
artikel
|
| 25 |
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFκB pathway
|
Tanic, Miljana
|
|
2011
|
134 |
1 |
p. 41-51
|
artikel
|
| 26 |
Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
|
Kajitani, Keiko
|
|
2012
|
134 |
1 |
p. 139-155
|
artikel
|
| 27 |
Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients
|
Fumagalli, Caterina
|
|
2012
|
134 |
1 |
p. 131-137
|
artikel
|
| 28 |
Molecular insights on basal-like breast cancer
|
Valentin, Mev Dominguez
|
|
2012
|
134 |
1 |
p. 21-30
|
artikel
|
| 29 |
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
|
Santarpia, Libero
|
|
2012
|
134 |
1 |
p. 333-343
|
artikel
|
| 30 |
MUTYH gene variants and breast cancer in a Dutch case–control study
|
Out, Astrid A.
|
|
2012
|
134 |
1 |
p. 219-227
|
artikel
|
| 31 |
Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)
|
Neugut, Alfred I.
|
|
2012
|
134 |
1 |
p. 419-428
|
artikel
|
| 32 |
Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
|
Zhao, Xiangshan
|
|
2012
|
134 |
1 |
p. 171-180
|
artikel
|
| 33 |
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer
|
Schoppmann, Sebastian F.
|
|
2012
|
134 |
1 |
p. 237-244
|
artikel
|
| 34 |
Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery
|
Levy, Ellen W.
|
|
2012
|
134 |
1 |
p. 315-324
|
artikel
|
| 35 |
Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer
|
Snape, Katie
|
|
2012
|
134 |
1 |
p. 429-433
|
artikel
|
| 36 |
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
|
Fostira, Florentia
|
|
2012
|
134 |
1 |
p. 353-362
|
artikel
|
| 37 |
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer
|
Munzone, Elisabetta
|
|
2012
|
134 |
1 |
p. 277-282
|
artikel
|
| 38 |
Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation
|
Shubbar, Emman
|
|
2011
|
134 |
1 |
p. 71-80
|
artikel
|
| 39 |
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
|
Nes, J. G. H. van
|
|
2012
|
134 |
1 |
p. 267-276
|
artikel
|
| 40 |
Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls
|
Jeffe, D. B.
|
|
2012
|
134 |
1 |
p. 379-391
|
artikel
|
| 41 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer
|
Kamal, A. H.
|
|
2012
|
134 |
1 |
p. 371-378
|
artikel
|
| 42 |
SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE)
|
Wang, Chunyu
|
|
2011
|
134 |
1 |
p. 101-115
|
artikel
|
| 43 |
Stromal–epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer
|
Xu, Cong
|
|
2012
|
134 |
1 |
p. 157-169
|
artikel
|
| 44 |
T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors
|
Wang, Li-Xin
|
|
2011
|
134 |
1 |
p. 61-70
|
artikel
|
| 45 |
The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?
|
Massabeau, Carole
|
|
2012
|
134 |
1 |
p. 259-266
|
artikel
|
| 46 |
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer
|
Gravgaard, Karina H.
|
|
2012
|
134 |
1 |
p. 207-217
|
artikel
|
| 47 |
Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin
|
Abu Ajaj, Khalid
|
|
2012
|
134 |
1 |
p. 117-129
|
artikel
|
Tijdschrift beschrijving